drugset / Trial / NCT00490490
Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the response rate of patients with relapsed or refractory low-grade or transformed low-grade, CD20-positive, B-cell non-Hodgkin's lymphoma to Iodine-131 (I-131) tositumomab (Bexxar) therapy plus local palliative radiation therapy (XRT).
Timeline
- Start
- 2007-01
- Primary completion
- 2011-06
- Completion
- 2013-07
Outcome
Outcome not reported
Stopped (Enrollment): “Low Accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tositumomab | Monoclonal antibody | — | — |
| Background | potassium iodide | Small molecule | 4 unknown | Oral |
| Background | potassium iodide | Small molecule | 20 unknown | Oral |
| Background | potassium iodide | Small molecule | 130 mg | Oral |